St. Francis Medical Center offers monoclonal antibody infusion treatments for COVID-19 patients with mild to moderate symptoms as part of the Food & Drug Administration (FDA)’s Emergency Use Authorization. The goal of the monoclonal antibody treatment is to reduce the risk for hospitalization in COVID-19 patients.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses, and in this case specifically directed against the spike protein of COVID-19.
Patients who meet the following criteria may qualify for the infusion therapy:
- Positive COVID-19 test
- 18 years of age or older
- Mild to moderate COVID-19 symptoms
- No recent hospitalization due to COVID-19
- No oxygen supplementation
- Within 7 days of first showing symptoms
All patients must arrive at the Emergency Department at St. Francis for triage. If treatment is deemed appropriate, patients will be transported to the Infusion Clinic.
The treatment takes approximately two hours. Patients who believe they may be a candidate for the treatment should contact their primary care physician.